Novo Nordisk, Sanofi and Eli Lilly face court in US over insulin prices
Two claims against the companies have been dropped, but one has been upheld.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
Novo Nordisk, Sanofi and Eli Lilly are facing racketeering charges in the US over their insulin prices.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biden starts new offensive to bring down medicine prices
For subscribers
Eli Lilly welcomes competition for cheap insulin in US
For subscribers
